Business
Announces Participation in Research Programme
Announces Participation in Research Programme.
About this update from Creo Medical Group Plc
[{"type":"text","content":"\n \nRNS Number : 1214Y Creo Medical Group PLC 01 March 2017 \n\nCreo Medical Announces Participation in SUMCASTEC Research Programme\n \nMultidisciplinary Consortium Awarded €4 Million Grant\n \nProgramme Focused on Isolation and Neutralization of Cancer Stem Cells\n \nChepstow, South Wales, 1 March 2017 - Creo Medical Group plc (AIM: CREO) (\"Creo\" or the \"Company\"), a medical device company focused on the emerging field of surgical endoscopy, announces its participation in the Semiconductor-based Ultrawideband Micromanipulation of Cancer Stem Cells (\"SUMCASTEC\") H2020 FET OPEN research programme, led by the XLIM Research Institute at the University of Limoges in France.\n \nCreo is one of six European partners gathered in a multidisciplinary consortium aimed at developing a novel and innovative micro-optofluidic lab-on-chip (LOC) platform deploying semi-conductor technology to neutralize cancer stem cells with electromagnetic waves. The consortium has been awarded a €4 million (£3.4 million) grant, €530,000 (£450,000) of which is allocated to Creo.\n \nSUMCASTEC is based on the isolation, followed by the neutralisation of cancer cells associated with some of the most aggressive brain tumours, specifically Glioblastoma Multiforme and Medulloblastoma. Brain cancers are among the most difficult tumours to treat and remain a leading cause of death in Europe (57,000 new cases and 45,000 deaths were reported by World Health Organisation in Europe in 2012).\n \nCreo will lead on the development of the cell neutralisation aspect of the programme with a view to the potential commercialisation of the LOC device so that can be used in-situ. Certain aspects of this project are closely related to the work already being undertaken by Creo for the treatment of lung tumours.\n \nChris Hancock, Chief Technology Officer of Creo Medical, said:\n\"We are excited to be part of the SUMCASTEC consortium, which brings together well-respected neurologists, microbiologists and engineers. This grant recognises the potential of Creo Medical's innovative ablation technology and its potential application in new and challenging fields. This new system has the potential to provide a new treatment option for some of the most aggressive brain tumours.\"\n \nArnaud Pothier, main project leader and CNRS senior ...